RenovoRx (Nasdaq:RNXT) announced that it priced an underwritten public offering of common stock worth proceeds of $12.1 million. Mountain View, California-based RenovoRx priced more than 11.5 million shares of common stock at $1.05 per share. It expects the proceeds to total approximately $12.1 million before deducting underwriting discounts, commissions and offering expenses. The company plans […]
RenovoRx
RenovoRx to increase production of RenovoCath catheter delivery system
RenovoRx announced today that it plans to increase the production of its RenovoCath catheter-based delivery system. The Los Altos, California-based company cited increased demand for the delivery of diagnostic and/or therapeutic agents. It signed a new project work order with its principal manufacturing partner, Medical Murray, providing for an expanded relationship. The company looks to […]
RenovoRx raises $11.1M to support oncology drug delivery trial
RenovoRx (Nasdaq:RNXT) announced today that it closed a private placement worth gross proceeds of approximately $11.1 million. The $11.1 million adds to a separate private placement that brought in proceeds of approximately $6.1 million in January. RenovoRx plans to use the funds to strengthen its balance sheet and extend its cash runway into 2026. Funds […]
RenovoRx closes $6.1M private placement
RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million. Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds […]
RenovoRx, Imugene collab on oncolytic virus therapy delivery
RenovoRx (Nasdaq:RNXT) announced that it entered into a strategic research collaboration with Imugene to optimize oncolytic virus therapy delivery. Utilizing RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform), the companies hope to enhance the treatment of difficult-to-access tumors. “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally […]
RenovoRx appoints new SVP of clinical operations
RenovoRx (Nasdaq:RNXT) announced today that it appointed Leesa Gentry as senior vice president of clinical operations. Los Altos, California-based RenovoRx said Gentry brings with her “valuable leadership experience” to advance the company’s cancer treatment studies. She becomes the fourth addition to the company’s executive management team in the last year. That group includes COO Angela […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
RenovoRx sets its sights on localized treatment of pancreatic cancer
People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter […]
RenovoRx raises $7m for drug-device pancreatic cancer therapy
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds […]
RenovoRx wins label expansion for RenovoCath device
RenovoRx said yesterday that it won label expansion for the RenovoCath dual-balloon infusion catheter to include the delivery of chemotherapeutics. The device isolates segments of the peripheral vasculature, allowing doctors to deliver therapeutics in a more targeted fashion, according to the Los Altos, Calif.-based company. “This additional FDA indication marks yet another milestone for RenovoRx as […]
